

BCI Society

Conflict of Interest Disclosure Form

The BCI Society aims for independence, objectivity, and diversity in all its activities. In order to avoid conflicts of interest, all Board nominees and Board members are required to fill out this Conflict of Interest Disclosure Form to disclose relevant financial and in-kind relationships with industrial parties acting in the BCI field, or other organizations that could represent a conflict of interest. Full disclosure is expected even when it is not clear whether or not a specific relationship constitutes a conflict of interest. Relevant financial interests are defined according to the criteria applied by the NIH, as listed in section D8 of <https://grants.nih.gov/faqs#/financial-conflict-of-interest.htm?anchor=52857>. Briefly, any financial interest larger than 5000 USD needs to be reported.

The completed conflict of interest disclosure form of Board nominees will be shared with the membership for evaluation during the election process.

The completed conflict of interest disclosure form of Board members are posted on the BCI Society website. Any relevant changes need to be reported to the Board within 30 days and the conflict of interest disclosure form needs to be updated accordingly.

Please disclose all relationships over the previous three calendar years of yourself as well as of first-degree relatives.

Nature of relationship or affiliation	Company / Organization Name	Company / Organization Name	Company / Organization Name
<i>1. Equity interests</i> Equity interests (or entitlement to same) of stocks, stock options, royalties, etc., including income from patents or copyrights			
<i>2. Director or employee</i> Service as a director or employment by a commercial organisation, whether or not remuneration is provided for such service			
<i>3. Owner enterprise</i> Sole ownership, partnership, or principal of a commercial enterprise			

<p>4. <i>Ownership of patent(s)</i> Please report patents related to industry and/or that have been sold/ licensed.</p>	<p>Horn CC, Xiao G, Bettinger C, Fedder GK, Ong XC, Huang W, Fisher LE, Gaunt RA. Conformable neural interface device with hydrogel adhesions and methods of using the same. PCT/US2018/043161. Fisher LE, Gaunt RA, Weber DJ. Treatment of phantom limb pain and diabetic neuropathy pain, and increasing prosthetic control, by stimulation of dorsal rootlets and lateral spinal cord. US Patent App. 16/845,691. Oct. 15, 2020. Sobinov A, Yakovenko S, Gritsenko V, Boots M, Gaunt RA, Collinger JL, Fisher LE. Systems and methods for approximating musculoskeletal dynamics. US Patent 11197769B2. Issued Dec. 14, 2021. Weber DJ, Gaunt RA, Bruns TM. Monitoring and regulating physiological states and functions via sensory neural inputs to the spinal cord. US Patent No. 11,433,241. Issued Sept. 9, 2022. Fisher LE, Gaunt RA, Weber DJ. Treatment of phantom limb pain and diabetic neuropathy pain, and increasing prosthetic control, by stimulation of dorsal rootlets and lateral spinal cord. US Patent No. 11 433 238</p>		
---	--	--	--

<p><i>5. Royalties</i> Receipt of royalties, including for intellectual property, such as a device or a diagnostic tool</p>			
<p><i>6. Company consultant</i> Consultant to company including positions on medical or scientific advisory boards</p>	Blackrock Neurotech	Braingrade GmbH	Neuwired LLC
<p><i>7. Company speaker honoraria</i> Honoraria for speaking at company sponsored meetings or events.</p>			
<p><i>8. Industry research grants</i> Research grants, partial or full salary support from commercial organisation for self or employees for whom you are managerially responsible (i.e. laboratory technical/research fellow).</p>	Blackrock Neurotech	Ripple LLC	
<p><i>9. Other</i> Please indicate company/ organization, conflict type, type of financial or other relationship</p>			

I confirm that I do not have any existing or known future conflicts of interest to disclose.

I have answered fully and to the best of my ability and will update this form promptly when my circumstances change.

Name: Robert Gaunt

Date: Mar. 25, 2024